Advertisement

World Journal of Urology

, Volume 37, Issue 11, pp 2509–2515 | Cite as

Medical dissolution therapy for the treatment of uric acid nephrolithiasis

  • Chad M. Gridley
  • Michael W. Sourial
  • Amy Lehman
  • Bodo E. KnudsenEmail author
Original Article
  • 197 Downloads

Abstract

Introduction

Uric acid (UA) nephrolithiasis represents 10% of kidney stones in the US with low urine pH and high saturation of UA as the main risk factors for stone development. Dissolution therapy for UA kidney stones via urinary alkalization has been described as a treatment option. We present our experience in treating UA nephrolithiasis with medical dissolution therapy.

Methods

A retrospective review was performed of UA stone patients referred for surgery but treated with dissolution therapy between July 2007 and July 2016. Patients were identified using ICD-9 codes. Patients were treated with potassium citrate alone or in combination with allopurinol. Serial imaging and urine pH were obtained at follow-up. Demographics, aggregate stone size, time to stone clearance, urine pH (office dip), and complications were recorded.

Results obtained

Twenty-four patients (14 men and 10 women) were identified that started medical dissolution therapy for UA nephrolithiasis after initial referral for surgical management. Three patients (13%) did not tolerate the initiation of dissolution therapy and discontinued this treatment. Of the 21 patients that were maintained on dissolution therapy, 14 patients (67%) showed complete resolution of nephrolithiasis and 7 patients (33%) showed partial reduction. Patients with partial response had a mean reduction in stone burden of 68%. There were 3 recorded complications (UTI, GI upset with therapy, and throat irritation) and 4 recorded stone recurrences among these 21 patients.

Conclusion

Based on our study population, medical dissolution therapy is a well-tolerated, non-invasive option for UA nephrolithiasis.

Keywords

Uric acid Nephrolithiasis Dissolution Alkalization 

Abbreviations

AUA

American Urological Association

BMI

Body Mass Index

CT

Computed tomography

GI

Gastrointestinal

KUB

Kidney, ureter, and bladder X-ray

RUS

Renal ultrasound

SD

Standard deviation

UA

Uric acid

UTI

Urinary tract infection

Notes

Author contributions

CMG data collection, manuscript writing and editing. MWS data collection and manuscript editing. AL data analysis and manuscript editing. BEK study design, project development, and manuscript editing.

Source of funding

The authors have no competing interests to disclose.

Compliance with ethical standards

Conflict of interest

Bodo Knudsen is a consultant for Olympus Surgical, Boston Scientific, Thermedx, and Bard Medical. The remaining authors have no disclosures

Ethical approval

The study was approved by the Ohio State University Office of Responsible Research Practices Institutional Review Board (IRB) and conducted in accordance with this. Patient consent was waived by the IRB given the retrospective study design.

References

  1. 1.
    Pearle MS, Goldfarb DS, Assimos DG et al (2014) Medical management of kidney stones: AUA guideline. J Urol 192(2):316–324CrossRefGoogle Scholar
  2. 2.
    Shekarriz B, Stoller ML (2002) Uric acid nephrolithiasis: current concepts and controversies. J Urol 168(4 Pt 1):1307–1314CrossRefGoogle Scholar
  3. 3.
    Maalouf NM, Cameron MA, Moe OW et al (2004) Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens 13(2):181–189CrossRefGoogle Scholar
  4. 4.
    Sakhaee K, Maalouf NM (2008) Metabolic syndrome and uric acid nephrolithiasis. Semin Nephrol 28(2):174–180CrossRefGoogle Scholar
  5. 5.
    Reichard C, Gill BC, Sarkissian C et al (2015) 100% uric acid stone formers: what makes them different? Urology 85(2):296–298.  https://doi.org/10.1016/j.urology.2014.10.029 (Epub 2014 Oct 30) CrossRefPubMedGoogle Scholar
  6. 6.
    Sinha M, Prabhu K, Venkatesh P et al (2013) Results of urinary dissolution therapy for radiolucent calculi. Int Braz J Urol 39(1):103–107CrossRefGoogle Scholar
  7. 7.
    Moran ME, Abrahams HM, Burday DE et al (2002) Utility of oral dissolution therapy in the management of referred patients with secondarily treated uric acid stones. Urology 59(2):206–210CrossRefGoogle Scholar
  8. 8.
    Petritsch PH (1977) Uric acid calculi: results of conservative treatment. Urology 10(6):536–538CrossRefGoogle Scholar
  9. 9.
    Ngo TC, Assimos DG (2007) Uric acid nephrolithiasis: recent progress and future directions. Rev Urol 9(1):17–27PubMedPubMedCentralGoogle Scholar
  10. 10.
    Straub M, Hautmann RE (2005) Developments in stone prevention. Curr Opin Urol 15:119–126CrossRefGoogle Scholar
  11. 11.
    Singh SK, Agarwal MM, Sharma S (2011) Medical therapy for calculus disease. BJU Int 107(3):356–368CrossRefGoogle Scholar
  12. 12.
    Tung KH, Tan EC, Foo KT (1984) Chemolysis of uric acid stones. Ann Acad Med Singapore 13(4):620–624PubMedGoogle Scholar
  13. 13.
    Cicerello E, Merlo F, Maccatrozzo L (2010) Urinary alkalization for the treatment of uric acid nephrolithiasis. Arch Ital Urol Androl 82(3):145–148PubMedGoogle Scholar
  14. 14.
    Penniston KL, Antonelli JA, Viprakasit DP et al (2017) validation and reliability of the Wisconsin stone quality of life questionnaire. J Urol 197(5):1280–1288CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of UrologyThe Ohio State University Wexner Medical CenterColumbusUSA
  2. 2.Center for BiostatisticsThe Ohio State UniversityColumbusUSA

Personalised recommendations